The Journal of Clinical Endocrinology & Metabolism · 2005 · 209 citations · 48 references
MedicineEndocrinologyInternal MedicineEndocrine PharmacotherapyGeneral Internal MedicineImmunotherapyComorbidityComorbidity AssessmentDiabetes MellitusHealth-related Quality Of LifeHealth-related Quality Of Life MeasurementMedical ComorbiditiesComorbidity AnalysisComorbidity ManagementComorbidity PrognosisDisease DurationSomatostatin Analog TherapyTreatment-related Quality Of Life
Active acromegaly is associated with significant comorbidity and reduced quality of life. However, the prevalence of comorbidity after long-term remission is not established. Therefore, we assessed the presence of comorbidity in 118 patients in long-term remission after surgery, radiotherapy, and/or somatostatin analog treatment according to strict biochemical criteria of serum GH and IGF-I concentrations and evaluated the impact of comorbidity on quality of life. The mean duration of remission was 12.0 +/- 7.4 yr, and mean actual IGF-I sd scores were 0.6 +/- 1.7. Self-reported joint problems occurred in 77% of patients, hypertension in 37%, a history of myocardial infarction in 9%, and diabetes mellitus in 11%. The presence of joint problems was not related to GH and IGF-I levels, active disease duration, or age. Joint complaints had significant negative impact on quality of life. Patients with a history of myocardial infarction had reduced scores for general health, depression, and fatigue, and diabetes mellitus was associated with reduced scores for anxiety and sleep. In conclusion, acromegalic patients had a high prevalence of joint-related comorbidity and hypertension despite long-term control of GH excess. Especially, joint complaints contributed to a reduced perceived quality of life in these patients.
48
The Hospital Anxiety and Depression Scale
A. S. Zigmond, R. P. Snaith · Acta Psychiatrica Scandinavica · 1983 · 46.6K citations